SCHEMBL3011269

SCHEMBL3011269

CCCc1ccc(-c2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.57
MAPK1 P28482 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
ALDH1A1 P00352 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
MAPT P10636 7/20 0.55
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
AR P10275 3/20 0.48
HTT P42858 1/20 0.46
PKM P14618 2/20 0.45
PKLR P30613 1/20 0.45
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000559 0.92 LMNA (0.59) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015200 0.90 SMN1; SMN2 (0.59) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3014464 0.87 SMN1; SMN2 (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015536 0.86 PKM (0.45) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011690 0.86 ALDH1A1 (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008963 0.85 LMNA (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3005812 0.85 LMNA (0.67) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3002766 0.85 SMN1; SMN2 (0.80) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3013174 0.85 SMN1; SMN2 (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3021992 0.85 MAPK1 (0.47) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.